SCHEMBL13957653

SCHEMBL13957653

CC1(C)OB(c2ccc(CN3CCOCC3)c(N)c2)OC1(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.43
CYP2C9 P11712 2/20 0.43
ALOX15 P16050 1/20 0.43
CYP2A13 Q16696 6/20 0.42
ROCK1 Q13464 1/20 0.38
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
CNR2 P34972 1/20 0.36
CTSB P07858 1/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
ATM Q13315 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
NCF1 P14598 1/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5254328 0.88 HSD17B10 (0.46) HSD17B10CYP2C9ALOX15CYP2A13ROCK1
SCHEMBL2801616 0.86 CYP2A13 (0.51) HSD17B10CYP2C9ALOX15CYP2A13ROCK1
SCHEMBL110824 0.85 CYP2A13 (0.58) HSD17B10CYP2C9ALOX15CYP2A13ROCK1
SCHEMBL428922 0.85 CYP2A13 (0.50) HSD17B10CYP2C9ALOX15CYP2A13ROCK1
SCHEMBL12909233 0.83 CYP2A13 (0.51) HSD17B10CYP2C9ALOX15CYP2A13KDM4E
SCHEMBL2800997 0.81 PDE3B (0.45) HSD17B10CYP2C9ALOX15CYP2A13ROCK1
SCHEMBL424879 0.81 TBK1 (0.42) HSD17B10CYP2C9ALOX15CYP2A13ROCK1
SCHEMBL18580216 0.81 L3MBTL1 (0.42) ROCK1KDM4EALDH1A1KMT2AMEN1
SCHEMBL146568 0.78 HRH3 (0.56) ALDH1A1LMNAMAPTLPLLIPG
SCHEMBL13957871 0.77 POLB (0.44) HSD17B10ALOX15KDM4EALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009010488-A1 HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS NOVARTIS AG (CH) 2009-01-22 WO disclosed